Methods of Using FIX Polypeptides
AssigneeBioverativ Therapeutics Inc.
InventorsGlenn PIERCE, Samantha TRUEX, Robert T. PETERS, Haiyan JIANG
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
Claims34
A method of reducing or decreasing an annualized bleeding rate in a human subject in need thereof, comprising administering to the subject multiple doses of 10 IU/kg to 200 IU/kg of a chimeric Factor IX (FIX) polypeptide, comprising FIX and an FcRn binding partner (FcRn BP), at a dosing interval of once a week or longer, wherein the annualized bleeding rate of the bleeding episodes is less than 10.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of reducing or decreasing an annualized bleeding rate in a human subject in need of controlling a bleeding disorder for on-demand treatment or perioperative management, comprising administering to the subject multiple doses of 10 IU/kg to 200 IU/kg of a chimeric Factor IX (FIX) polypeptide, comprising FIX and a FcRn binding partner (FcRn BP), wherein the annualized bleeding rate of the bleeding episode is less than 26.
(canceled)
14-17. (canceled)
19-32. (canceled)
34-35. (canceled)
42-48. (canceled)
(canceled)
53-58. (canceled)
(canceled)
62-130. (canceled)
Dependencies are inferred from the claim text.